Jim Tananbaum is a major investor in healthcare, and his recent venture is in mental illness treatment. A top ranking entrepreneur on Forbes’ Midas List, Jim is in partnership with Mindstrong Health to develop a technology for the cure of mental disorders.
Mindstrong Health is a tech start-up that is developing an AI platform that will diagnose neuropsychiatric disorders in patients. Mindstrong’s approach is simple, their technology will tap into the pattern interactions we have with our phones on a daily basis. In a report by endpts.com, this AI platform uses the parameters of speed, memory, attention and cognitive function to gauge the neuropsychiatric well-being of a patient.
According to businesswire.com, before this breakthrough, the medical fraternity was plagued with the challenge of providing adequate care for mental patients. Unlike other diseases that are properly diagnosed through careful analyses of collected data, the treatment of psychiatric disorders takes a more subjective approach. This approach in itself was flawed given the open loopholes for misdiagnosis. Mindstrong Health, through their technology, aims to provide a modernized way of collecting tangible data for proper diagnosis of mental patients.
Jim Tananbaum is one of the investors who immediately bought this idea. Given his long history of investing in the healthcare system, he saw the importance of Mindstrong’s vision towards an improved healthcare system for neuropsychiatric patients. Mr. Jim Tananbaum was the moderator of the recent fundraises held to raise capital to fund Mindstrong’s new project. Jim Tananbaum was joined by other investors that included ARCH Venture Partners, Berggruen Holdings, Optum Ventures, and One Mind Brain Health Impact Fund.
Mindstrong Health is confident that they will roll out the first stage of clinical tests as they aim to refine their new technology before making it public. The medical fraternity, on the other hand, is hopeful that they will now have a more concrete approach to properly diagnose and cure mental disorders.
About Jim Tananbaum
Jim Tananbaum is an avid investor in healthcare systems, reveals Peloton Therapeutics. Through his company, Foresite Capital, he manages an array of assets that are well worth over $1.1 billion. After graduating from Harvard School of Business, Jim found his first pharmaceutical company, GelTex. GelTex successfully launched two FDA approved drugs into the medical market generating $1 billion in profits.
Mr. Tananbaum is also a partner in several investments suits which included Sierra Ventures and Prospect Venture Partner. Today Jim Tananbaum is ranked as one of the top 100 investors in Forbes Midas List. Learn more about Jim, visit his about.me page.